THIRD QUARTER AND NINE MONTHS RESULTS 2011
Revenue for the third quarter declined by 2 percent at constant exchange rates (CER) to $8,213 million. -Strong revenue growth for Crestor, Seroquel XR and Symbicort. -Revenue performance reflects the loss of more than $350 million of revenue from generic competition, as well as the impact of government price interventions. -Emerging Markets revenue increased by 7 percent at CER in the third quarter; revenue was up 10 percent for the nine months. Core operating profit in the third quarter was $3,177 million, down 2 percent at CER, in line with the decline in revenue. -Core